Search

835 Result(s)
Sort by

BI_X_Shanghai

BI_X_Shanghai

Boehringer Ingelheim opens a second branch of its digital lab in Shanghai
Scouting for digital innovation

Scouting for digital innovation

Get to know our digital scouts who look-out for emerging technologies and trends that could benefit our patients.
Really Digital, Mr Hach!

Really Digital, Mr Hach!

The Head of User Experience and SCRUM at Boehringer Ingelheim’s digital lab BI X offers a glimpse into his work and motivation.
Digital solutions save lives

Digital solutions save lives

Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.
Reimagining digital healthcare worldwide

Reimagining digital healthcare worldwide

How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes
Partnership-with-clicktherapeutics

Partnership-with-clicktherapeutics

Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
digital_leader_award_2020

digital_leader_award_2020

Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award
BI_PharmAccess_launch_digital_healthcare_program

BI_PharmAccess_launch_digital_healthcare_program

Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
Kicking off 2024 with five new R&D partnerships

Kicking off 2024 with five new R&D partnerships

We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
biolabs-heidelberg

biolabs-heidelberg

Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
clinical-collaboration-with-Amgen

clinical-collaboration-with-Amgen

Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
Global mobility

Global mobility

We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.
Strategic-collaboration-with-EnaraBio

Strategic-collaboration-with-EnaraBio

Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
BI Access to Healthcare Strategy_Availability

BI Access to Healthcare Strategy_Availability

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.